Latest Healthcare Research Reports

Tag: targeted therapy

  • Oncogene Inhibitor  Market Research: Growth Projections and Trends 2030

    Oncogene Inhibitor  Market Research: Growth Projections and Trends 2030

    Uncover key drivers, emerging technologies, and competitive movements shaping the oncogene inhibitor  market from 2026–2035 with trusted insights from The Business Research Company

    Starting from its 2026 valuation, what market size is the Oncogene Inhibitor  Market expected to reach by 2030?

    The market for oncogene inhibitors has demonstrated robust expansion over recent years. It is projected to increase from $43.27 billion in 2025 to $47.11 billion in 2026, registering a compound annual growth rate (CAGR) of 8.9%. Historically, this market’s expansion can be ascribed to the limited availability of targeted therapies, a reliance on conventional chemotherapy, the growing prevalence of cancer, the expanding infrastructure of hospitals and specialty clinics, and increasing awareness about oncogene-targeted treatments.

    The oncogene inhibitor market size is projected to experience robust expansion over the coming years. This market is set to reach $65.45 billion by 2030, showing a compound annual growth rate (CAGR) of 8.6%. Factors contributing to this growth during the forecast period include progress in small molecule inhibitors and biologics, the broadening of gene therapy and monoclonal antibody research, increasing uptake of personalized medicine, growing R&D investments focused on oncology, and the incorporation of digital health and AI into cancer treatment. Key trends anticipated for the forecast period involve the increasing development of targeted cancer therapies, a greater embrace of oral and injectable oncogene inhibitors, the broadening of combination therapy strategies, an intensified focus on personalized medicine, and more extensive research into rare and challenging-to-treat cancers.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24635&type=smp

    What Drivers Are Driving Adoption Within The Oncogene Inhibitor  Market?

    The anticipated rise in cancer prevalence is poised to drive the expansion of the oncogene inhibitor market in the future. Cancer is defined as a collection of illnesses marked by the unregulated proliferation and dissemination of atypical cells within the body. The rise in cancer cases is linked to unhealthy lifestyle choices, where habits like smoking, inadequate nutrition, insufficient physical activity, and alcohol consumption compromise the body’s defenses and foster the development of malignant cells. Oncogene inhibitors assist in cancer treatment by targeting and inhibiting particular genes responsible for promoting cancer cell proliferation, consequently retarding or halting tumor formation and advancement. For example, a report released by Cancer Research UK, a UK-based charitable organization, in July 2024, projected that the average yearly count of new melanoma skin cancer instances in the UK would climb from about 20,800 during 2023-2025 to roughly 26,500 by 2038-2040. Consequently, the growing prevalence of cancer is fueling the expansion of the oncogene inhibitor market.

    What Segments Are Included Within The Oncogene Inhibitor  Market?

    The oncogene inhibitor  market covered in this report is segmented –

    1) By Type: Oral, Injection

    2) By Drug Class: Small Molecule Drugs, Biologics, Combination Therapies

    3) By Indication: Breast Cancer, Ovarian Cancer, Lung Cancer, Pancreas Cancer, Other Indications

    4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    5) By End-Users: Hospitals, Specialty Clinics, Other End-Users

    Subsegments:

    1) By Oral Oncogene Inhibitors: Small Molecule Inhibitors, Targeted Therapy Pills, Tyrosine Kinase Inhibitors (TKIs)

    2) By Injection Oncogene Inhibitors: Monoclonal Antibodies (mAbs), Peptide Receptor Radioligand Therapy (PRRT), Small Molecule Inhibitors (Injectable), Gene Therapy Injections

    What Trends Are Expected To Impact The Competitive Landscape Of The Oncogene Inhibitor  Market?

    Companies operating in the oncogene inhibitor market are heavily invested in creating advanced treatment options, including novel functional genomic approaches, to boost the precision and effectiveness of cancer therapies. Novel functional genomic approaches involve sophisticated methodologies that integrate diverse genomic, transcriptomic, and epigenomic data to decipher gene functions and their contributions to diseases such as cancer. For example, in May 2024, Delphia Therapeutics, a biotechnology firm based in the US, introduced a new method called activation lethality, aimed at exploiting cancer’s susceptibility to oncogene overactivation. Noted oncology drug developers Kevin Marks, Bill Sellers, and Mike Dillon have secured $67 million in funding to advance this particular strategy. Activation lethality specifically targets the excessive activation of oncogenes, which are genes capable of driving cancer development when mutated or highly expressed. Some cancer cells depend on this heightened activity for their survival, and by inducing lethal stress through precise intervention, this technique selectively eliminates those cancer cells while preserving healthy ones.

    Who Are The Core Companies Influencing Trends In The Oncogene Inhibitor  Market?

    Major companies operating in the oncogene inhibitor  market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Mirati Therapeutics Inc., AstraZeneca PLC, Incyte Corporation, Blueprint Medicines Corporation, Astex Pharmaceuticals Inc., G1 Therapeutics Inc., Nurix Therapeutics Inc., GenFleet Therapeutics Co Ltd., Relay Therapeutics Inc.

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/oncogene-inhibitor-global-market-report

    Which Regions Are Projected To Dominate The Oncogene Inhibitor  Market In The Coming Years?

    North America was the largest region in the oncogene inhibitor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncogene inhibitor  market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Oncogene Inhibitor  Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=24635&type=smp

    Browse Through More Reports Similar to the Global Oncogene Inhibitor  Market 2026, By The Business Research Company

    Oncolytic Virus Therapy Market Report 2026

    https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

    Generic Oncology Drugs Market Report 2026

    https://www.thebusinessresearchcompany.com/report/generic-oncology-drugs-global-market-report

    Antiglaucoma Drugs Market Report 2026

    https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Gastrointestinal Cancer Market Size Projected to Reach $42.45 Billion During the Forecast Period

    Global Gastrointestinal Cancer Market Size Projected to Reach $42.45 Billion During the Forecast Period

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    What Is The Anticipated Size Of The Gastrointestinal Cancer Market Over The Five-Year Period 2025–2029?

    The gastrointestinal cancer market size has experienced swift expansion in recent years. It is anticipated to increase from $24.09 billion in 2024 to $27.05 billion in 2025, reflecting a compound annual growth rate (CAGR) of 12.3%. The historical growth of this market is attributable to the increasing incidence of gastrointestinal cancers, rising consumption of tobacco and alcohol, an expanding elderly demographic, inadequate dietary practices, and continuous developments in oncology diagnostics and therapies.

    Significant expansion is anticipated for the gastrointestinal cancer market size over the coming years. This market is projected to reach $42.45 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 11.9%. Factors contributing to this growth during the forecast period include the increasing uptake of biomarker-driven treatments, greater awareness regarding early detection, the expansion of healthcare infrastructure, governmental efforts in cancer care, and an increased emphasis on less invasive medical procedures. Key trends expected within the forecast timeframe encompass technological improvements in diagnostic instrumentation, novel developments in targeted treatments, advancements in immunotherapy, the expanding application of artificial intelligence in treating cancer, and continuous investigative efforts in precision oncology.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24546&type=smp

    Which Drivers Are Shaping The Gastrointestinal Cancer Industry’s Market Share?

    The increasing acceptance and use of targeted therapies are anticipated to boost the expansion of the gastrointestinal cancer market in the future. These therapies work by precisely inhibiting the multiplication of cancer cells, focusing on particular molecular targets while minimizing damage to healthy cells. Specifically, they are engineered to target distinct molecular pathways or genetic alterations that fuel disease progression, particularly in cancerous conditions. In contrast to conventional treatments such as chemotherapy, which indiscriminately attack both healthy and cancerous cells, targeted therapies concentrate on the specific attributes of an individual patient’s illness. For gastrointestinal (GI) cancer, these therapies operate by influencing particular genes or proteins responsible for tumor development, thereby providing a more accurate and potent treatment approach. This leads to improved patient results and a reduction in adverse effects compared to standard chemotherapy. An example illustrating this trend is that in July 2023, data from the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, indicated that there were 247 gene therapies in Phase II at the close of quarter one (Q1) 2023, a figure that increased by 5% to 260 by the end of quarter two (Q2). Consequently, the increasing adoption of targeted therapies is propelling the expansion of the gastrointestinal cancer market.

    How Is The Gastrointestinal Cancer Market Segmented?

    The gastrointestinal cancer market covered in this report is segmented –

    1) By Cancer Type: Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer, Other Cancer Types

    2) By Diagnostics: Endoscopy, Biopsy, Molecular Diagnostics, Imaging, Other Diagnostics

    3) By Treatment: Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery, Other Treatments

    4) By End-User: Hospitals, Oncology Centers, Research Institutes, Diagnostic Laboratories, Other End-Users

    Subsegments:

    1) By Colorectal Cancer: Colon Cancer, Rectal Cancer, Recurrent Colorectal Cancer, Metastatic Colorectal Cancer

    2) By Stomach Cancer: Adenocarcinoma, Gastrointestinal Stromal Tumors (GIST), Lymphoma, Carcinoid Tumors

    3) By Esophageal Cancer: Adenocarcinoma, Squamous Cell Carcinoma, Small Cell Carcinoma, Other Rare Esophageal Tumors

    4) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Endocrine (Neuroendocrine) Pancreatic Tumors, Metastatic Pancreatic Cancer, Resectable Or Unresectable Tumors

    5) By Liver Cancer: Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma, Hepatoblastoma, Secondary (Metastatic) Liver Cancer

    6) By Other Cancer Types: Small Intestine Cancer, Anal Cancer, Gallbladder Cancer, Gastrointestinal Carcinoid Tumor

    Which Ongoing Trends Are Expected To Shape The Gastrointestinal Cancer Market Outlook?

    Leading companies in the gastrointestinal cancer market are focusing on developing advanced solutions, such as monoclonal antibody treatment, to enhance patient survival rates and reduce side effects related to treatment. Monoclonal antibody treatment functions by employing laboratory-created antibodies that precisely identify and bind to cancer cells, aiding the immune system in targeting and eliminating them. For example, in September 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, launched VYLOY (zolbetuximab) for use in combination with fluoropyrimidine- and platinum-containing chemotherapy, following its approval from the European Commission. This medication is a first-line treatment for adults suffering from locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma where tumors express claudin 18.2 (CLDN18.2). With this approval, VYLOY becomes the first and sole therapy available in the European Union that targets CLDN18.2, a biomarker present in approximately 38% of these patients, a finding supported by positive clinical trial data from the SPOTLIGHT and GLOW studies.

    Which Global Market Leaders Are Shaping The Future Of The Gastrointestinal Cancer Sector?

    Major companies operating in the gastrointestinal cancer market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol‑Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Parexel International Corporation, Ipsen Biopharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Boehringer Ingelheim International GmbH, Zai Lab Limited, Taiho Pharmaceutical Co. Ltd.

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-cancer-global-market-report

    What Are The Key Regional Factors Influencing The Gastrointestinal Cancer Market Growth?

    North America was the largest region in the gastrointestinal cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Version Of The Gastrointestinal Cancer Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=24546&type=smp

    Browse Through More Reports Similar to the Global Gastrointestinal Cancer Market 2025, By The Business Research Company

    Intestine Cancer Therapeutics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report

    Gastric Cancer Drugs Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

    Colorectal Cancer Drugs Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Oncogene Inhibitor  Market Forecast: What to Expect by 2029

    Oncogene Inhibitor  Market Forecast: What to Expect by 2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    What Are The Forecasted Market Size Estimates For The Oncogene Inhibitor  Market Between 2025 And 2029?

    The oncogene inhibitor market has shown significant growth in recent years. Its valuation is predicted to expand from $39.68 billion in 2024 to $43.27 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.0%. This historical expansion can be linked to several contributing factors, such as an increase in resistance mechanism research, the development of targeted therapies, a heightened emphasis on research for lung cancer treatments, greater investment in kras and myc inhibitors, and a rise in funding and grants.

    The oncogene inhibitor market is projected to experience robust expansion in the coming years, with its size anticipated to reach $60.36 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.7%. This projected growth during the forecast period can be attributed to several factors, including heightened investments in healthcare, an expanding emphasis on tumor-agnostic therapies, increased embrace of targeted therapies, a supportive regulatory and reimbursement environment, and advancements in personalized therapy and companion diagnostics. Key trends anticipated within this forecast period encompass the development of next-generation KRAS inhibitors, the application of AI in drug discovery, the integration of real-time liquid biopsy, strategies for tumor microenvironment modulation, and the innovation of targeted nanoparticle drug delivery.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24635&type=smp

    Which Drivers Are Supporting Growth Of The Oncogene Inhibitor  Market?

    The oncogene inhibitor market is projected to experience growth going forward, driven by the escalating prevalence of cancer. Cancer is defined as a collection of diseases characterized by the uncontrolled division and spread of atypical cells within the body. This increase in cancer cases stems from unhealthy lifestyle practices, such as smoking, poor dietary habits, insufficient exercise, and alcohol consumption, all of which compromise the body’s defenses and encourage the multiplication of cancerous cells. Oncogene inhibitors aid in cancer treatment by specifically targeting and deactivating genes that stimulate cancer cell growth, thus retarding or halting tumor formation and advancement. For example, a report issued in July 2024 by Cancer Research UK, a UK-based charity, indicates that the average annual count of new melanoma skin cancer cases in the UK is anticipated to climb from roughly 20,800 between 2023-2025 to about 26,500 during the period 2038-2040. Therefore, the rising prevalence of cancer is a significant factor propelling the expansion of the oncogene inhibitor market.

    How Is The Oncogene Inhibitor  Market Classified Into Different Segments?

    The oncogene inhibitor  market covered in this report is segmented –

    1) By Type: Oral, Injection

    2) By Drug Class: Small Molecule Drugs, Biologics, Combination Therapies

    3) By Indication: Breast Cancer, Ovarian Cancer, Lung Cancer, Pancreas Cancer, Other Indications

    4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    5) By End-Users: Hospitals, Specialty Clinics, Other End-Users

    Subsegments:

    1) By Oral Oncogene Inhibitors: Small Molecule Inhibitors, Targeted Therapy Pills, Tyrosine Kinase Inhibitors (TKIs)

    2) By Injection Oncogene Inhibitors: Monoclonal Antibodies (mAbs), Peptide Receptor Radioligand Therapy (PRRT), Small Molecule Inhibitors (Injectable), Gene Therapy Injections

    What Are The Latest Industry Trends Transforming The Oncogene Inhibitor  Market?

    Major companies operating in the oncogene inhibitor market are prioritizing the development of innovative treatment options, such as advanced functional genomic approaches, to enhance the precision and effectiveness of cancer therapies. Novel functional genomic approaches refer to sophisticated methodologies that integrate various genomic, transcriptomic, and epigenomic data to understand gene functions and their roles in diseases like cancer. For instance, in May 2024, Delphia Therapeutics, a US-based biotechnology company, introduced a novel approach known as activation lethality to exploit cancer’s vulnerability to oncogene overactivation. Leading oncology drug developers Kevin Marks, Bill Sellers, and Mike Dillon have secured $67 million in funding to advance this strategy. Activation lethality targets the excessive activation of oncogenes, genes that, when mutated or highly expressed, can drive cancer development. Some cancer cells rely on this overactivation for survival, and by inducing lethal stress through targeted intervention, this approach selectively eliminates those cancer cells while preserving healthy ones.

    Who Are The Prominent Global Companies Shaping The Oncogene Inhibitor  Market?

    Major companies operating in the oncogene inhibitor  market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Mirati Therapeutics Inc., AstraZeneca PLC, Incyte Corporation, Blueprint Medicines Corporation, Astex Pharmaceuticals Inc., G1 Therapeutics Inc., Nurix Therapeutics Inc., GenFleet Therapeutics Co Ltd., Relay Therapeutics Inc.

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/oncogene-inhibitor-global-market-report

    Which Region Currently Holds The Largest Share Of The Oncogene Inhibitor  Market?

    North America was the largest region in the oncogene inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncogene inhibitor  market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Version Of The Oncogene Inhibitor  Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=24635&type=smp

    Browse Through More Reports Similar to the Global Oncogene Inhibitor  Market 2025, By The Business Research Company

    Oncolytic Virus Therapy Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

    Generic Oncology Drugs Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/generic-oncology-drugs-global-market-report

    Antiglaucoma Drugs Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Future Demand and Leading Companies Shaping the Gastrointestinal Cancer Market to 2029

    Future Demand and Leading Companies Shaping the Gastrointestinal Cancer Market to 2029

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Are the Latest Market Insights for the Gastrointestinal Cancer Industry?

    In recent times, the market size for gastrointestinal cancer has seen swift expansion. Projected to escalate from a size of $24.09 billion in 2024 to $27.05 billion in 2025, it will present a compound annual growth rate (CAGR) of 12.3%. Factors contributing to growth during the historic period comprise of the increasing presence of gastrointestinal cancers, a rise in the consumption of tobacco and alcohol, population aging, unhealthy eating habits, and technological advancements in oncology diagnostics and therapy.

    The market size for gastrointestinal cancer is forecasted to experience substantial growth in the upcoming years, reaching $42.45 billion in 2029 with a compound annual growth rate (CAGR) of 11.9%. The predicted growth within this period can be linked to the rising use of biomarker-driven therapies, increased recognition of early screening’s importance, the growth of the healthcare infrastructure, cancer care initiatives by the government, and a growing emphasis on minimally invasive methods. Significant trends during the forecast period involve advances in diagnostic tool technology, novel developments in targeted therapies, progress in immunotherapy, the escalated use of artificial intelligence in cancer treatments, and active research and development in precise oncology.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24546&type=smp

    What Forces Are Driving The Growth Of The Gastrointestinal Cancer Industry?

    The burgeoning use of precision medicine, such as targeted therapies, is propelling the developmental trajectory of the gastrointestinal cancer market. These targeted therapies, which disrupt the growth of cancerous cells by acting on unique molecular targets while minimizing harm to healthy cells, offer more specificity than traditional treatments. By focusing on specific molecular pathways or genetic mutations, these therapies can effectively treat cancer in a more individualized way. Unlike former treatments like chemotherapy that indiscriminately damage both healthy and malignant cells, targeted therapies are specific to each patient’s condition. For gastrointestinal (GI) cancer, these treatments act on particular genes or proteins that regulate tumor growth, allowing for personalized and effective approaches. This method leads to improved patient outcomes and fewer side effects compared to traditional chemotherapy methods. For instance, the American Society of Gene & Cell Therapy (ASGCT), and Citeline, both US-based entities, reported in July 2023 that the number of gene therapies in Phase II increased by 5% from quarter one (Q1) 2023, 247 therapies, to quarter two (Q2), 260 therapies. As such, the growth of the gastrointestinal cancer market is being fueled by the increased adoption of targeted therapies.

    What Is The Overview Of Market Segmentation In The Gastrointestinal Cancer Industry?

    The gastrointestinal cancer market covered in this report is segmented –

    1) By Cancer Type: Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer, Other Cancer Types

    2) By Diagnostics: Endoscopy, Biopsy, Molecular Diagnostics, Imaging, Other Diagnostics

    3) By Treatment: Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery, Other Treatments

    4) By End-User: Hospitals, Oncology Centers, Research Institutes, Diagnostic Laboratories, Other End-Users

    Subsegments:

    1) By Colorectal Cancer: Colon Cancer, Rectal Cancer, Recurrent Colorectal Cancer, Metastatic Colorectal Cancer

    2) By Stomach Cancer: Adenocarcinoma, Gastrointestinal Stromal Tumors (GIST), Lymphoma, Carcinoid Tumors

    3) By Esophageal Cancer: Adenocarcinoma, Squamous Cell Carcinoma, Small Cell Carcinoma, Other Rare Esophageal Tumors

    4) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Endocrine (Neuroendocrine) Pancreatic Tumors, Metastatic Pancreatic Cancer, Resectable Or Unresectable Tumors

    5) By Liver Cancer: Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma, Hepatoblastoma, Secondary (Metastatic) Liver Cancer

    6) By Other Cancer Types: Small Intestine Cancer, Anal Cancer, Gallbladder Cancer, Gastrointestinal Carcinoid Tumor

    What Future Market Trends Are Projected For The Gastrointestinal Cancer Industry?

    Key players in the gastrointestinal cancer market are concentrating their efforts on developing innovative solutions such as monoclonal antibody therapy to enhance patient survival rates while reducing the adverse effects associated with treatment. This form of treatment harnesses the power of lab-created antibodies that precisely recognize and attach to cancer cells, aiding the immune system in their targeted eradication. In a significant development, Astellas Pharma Inc., a pharmaceutical giant based in Japan, in September 2024, introduced VYLOY (zolbetuximab) in combination with fluoropyrimidine- and platinum-based chemotherapy. This treatment was approved by the European Commission. It represents a front-line defense for adults grappling with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinomas that show claudin 18.2 (CLDN18.2) expression in their tumors. With this approval, VYLOY becomes the pioneering and sole therapy in the European Union to target CLDN18.2, a biomarker present in approximately 38% of these patients. This approval draws its strength from the encouraging clinical trial results of the SPOTLIGHT and GLOW studies.

    Who Are The Primary Players Operating Across The Global Gastrointestinal Cancer Market?

    Major companies operating in the gastrointestinal cancer market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Parexel International Corporation, Ipsen Biopharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Boehringer Ingelheim International GmbH, Zai Lab Limited, Taiho Pharmaceutical Co. Ltd.

    Get The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-cancer-global-market-report

    Which Region Offers The Most Growth Potential For The Gastrointestinal Cancer Market Through 2029?

    North America was the largest region in the gastrointestinal cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=24546&type=smp

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • 2025 Oncogene Inhibitor  Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

    2025 Oncogene Inhibitor  Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What CAGR Is Anticipated for the Oncogene Inhibitor  Market Through 2029?

    The market for oncogene inhibitors has seen considerable growth in the past few years. Anticipated to expand from $39.68 billion in 2024 to $43.27 billion in 2025, with a compound annual growth rate (CAGR) of 9.0%. This historic growth can be credited to a surge in research around resistance mechanisms, the emergence of targeted therapies, an amplified focus on lung cancer treatment research, increased investments in kras and myc inhibitors, as well as escalating funding and grants.

    The market size for oncogene inhibitors is predicted to experience significant expansion in the impending years, with projections suggesting a growth to $60.36 billion by 2029, advancing at a compound annual growth rate (CAGR) of 8.7%. This anticipated growth within this period is associated with increased healthcare investments, the rising prominence of tumor-agnostic treatments, an escalating trend towards targeted therapies, encouraging regulatory and reimbursement structure, as well as customized therapy and companion diagnostics. Predicted trends for the forecast period comprise next-generation KRAS inhibitors, AI-powered drug discovery, the integration of real-time liquid biopsy, modulation of the tumor microenvironment, and targeted nanoparticle drug administration.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24635&type=smp

    What Market Forces Are Driving The Oncogene Inhibitor  Sector In 2025 And Beyond?

    The anticipated rise in cancer cases is predicted to boost the oncogene inhibitor market’s expansion in the future. The term “cancer” encompasses a variety of illnesses characterized by rampant and unregulated cell growth in the body. Unhealthy lifestyle practices, including smoking, a poor diet, inadequate physical activity, and alcohol consumption, facilitate the proliferation of cancerous cells. Oncogene inhibitors tackle cancer by focusing on and restricting certain genes that stimulate the growth of cancer cells, thereby halting or decelerating the formation and progress of tumors. For example, Cancer Research UK, a charity based in the UK, published a report in July 2024, indicating that the average yearly incidences of new melanoma skin cancer in the UK could escalate from roughly 20,800 in 2023-2025 to nearly 26,500 in 2038-2040. Consequently, the rise in cancer cases is fueling the expansion of the oncogene inhibitor market.

    How Is The Global Oncogene Inhibitor  Market Categorized By Segments?

    The oncogene inhibitor  market covered in this report is segmented –

    1) By Type: Oral, Injection

    2) By Drug Class: Small Molecule Drugs, Biologics, Combination Therapies

    3) By Indication: Breast Cancer, Ovarian Cancer, Lung Cancer, Pancreas Cancer, Other Indications

    4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    5) By End-Users: Hospitals, Specialty Clinics, Other End-Users

    Subsegments:

    1) By Oral Oncogene Inhibitors: Small Molecule Inhibitors, Targeted Therapy Pills, Tyrosine Kinase Inhibitors (TKIs)

    2) By Injection Oncogene Inhibitors: Monoclonal Antibodies (mAbs), Peptide Receptor Radioligand Therapy (PRRT), Small Molecule Inhibitors (Injectable), Gene Therapy Injections

    What Long-Term Trends Are Likely To Affect The Oncogene Inhibitor  Market?

    Top organizations in the oncogene inhibitor market are directing their efforts towards creating innovative treatment solutions, like the pioneering functional genomic methodologies, to improve the accuracy and effectiveness of cancer therapies. These trailblazing genomic approaches incorporate a variety of genomic, transcriptomic, and epigenomic data to comprehend gene functionalities and their relevance in conditions like cancer. As an illustration, Delphia Therapeutics, a biotech establishment located in the USA, rolled out an innovative technique known as activation lethality in May 2024, aiming to capitalize on cancer’s susceptibility to oncogene overactivation. Esteemed oncology medicine creators Kevin Marks, Bill Sellers, and Mike Dillon have obtained $67 million funding to propel this approach. Activation lethality zeroes in on the excessive sparking of oncogenes, which could spur cancer progression when they are mutated or express abundantly. Certain cancer cells are dependent on this overactivation to survive, and this strategy eliminates these cells selectively, saving the healthy ones by inducing lethal stress via targeted intervention.

    Which Firms Are Considered Leaders In The Oncogene Inhibitor  Market Space?

    Major companies operating in the oncogene inhibitor  market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Mirati Therapeutics Inc., AstraZeneca PLC, Incyte Corporation, Blueprint Medicines Corporation, Astex Pharmaceuticals Inc., G1 Therapeutics Inc., Nurix Therapeutics Inc., GenFleet Therapeutics Co Ltd., Relay Therapeutics Inc.

    Get The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/oncogene-inhibitor-global-market-report

    What Role Do Regional Policies And Investments Play In Oncogene Inhibitor  Market Expansion?

    North America was the largest region in the oncogene inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncogene inhibitor  market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=24635&type=smp

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Oncogene Inhibitor  Forecast Report – Designed for Decision Makers and Product Teams

    Oncogene Inhibitor  Forecast Report – Designed for Decision Makers and Product Teams

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Is the Growth Rate of the Oncogene Inhibitor  Market?

    In recent times, the oncogene inhibitor market has seen robust growth. The market is projected to escalate from $39.68 billion in 2024 to $43.27 billion in 2025, recording a compound annual growth rate (CAGR) of 9.0%. This growth in the historical period can be credited to an increase in research on resistance mechanisms, the popularity of targeted therapies, an escalating focus on research into treatments for lung cancer, augmented investment in kras and myc inhibitors, and a rise in funding and grants.

    What Growth Rate Is Forecasted for the Oncogene Inhibitor  Market by 2029?

    In the coming years, the market size of the oncogene inhibitor is anticipated to witness robust growth, expanding to $60.36 billion in 2029 with a compound annual growth rate (CAGR) of 8.7%. This projected growth during the forecast period can be linked to increased spending on healthcare, greater emphasis on tumor-agnostic treatments, rising utilization of targeted therapies, favorable regulatory and reimbursement conditions, as well as personalized treatment and companion diagnostics. Key trends for the forecast period involve next-generation KRAS inhibitors, AI-guided drug discovery, the integration of real-time liquid biopsy, modulation of tumor microenvironment, and directed nanoparticle drug conveyance.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24635&type=smp

    Which Key Companies Are Shaping the Future of the Oncogene Inhibitor  Market?

    Major companies operating in the oncogene inhibitor  market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Mirati Therapeutics Inc., AstraZeneca PLC, Incyte Corporation, Blueprint Medicines Corporation, Astex Pharmaceuticals Inc., G1 Therapeutics Inc., Nurix Therapeutics Inc., GenFleet Therapeutics Co Ltd., Relay Therapeutics Inc.

    Which Factors Are Driving Demand in the Oncogene Inhibitor  Industry?

    The rise in cancer prevalence is anticipated to fuel the expansion of the oncogene inhibitor market in the future. Cancer is a collection of diseases denoted by the rampant growth and dissemination of anomalous cells in the body. Unhealthy lifestyles are leading to an increase in cancer as habits like smoking, poor dietary habits, lack of physical activity, and alcohol consumption weaken the body and foster the propagation of carcinogenic cells. Oncogene inhibitors function in cancer treatment by zeroing in on and obstructing specific genes that spur cancer cell growth, thereby halting or decelerating tumor development and progression. For example, a report published by Cancer Research UK, a UK-based charity, in July 2024, estimates that the average annual new melanoma skin cancer cases in the UK will increment from nearly 20,800 in 2023-2025 to about 26,500 in 2038-2040. Consequently, the escalating prevalence of cancer is stimulating the oncogene inhibitor market’s growth.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=24635&type=smp

    How Is the Oncogene Inhibitor  Market Segmented by Several Divisions?

    The oncogene inhibitor  market covered in this report is segmented –

    1) By Type: Oral, Injection

    2) By Drug Class: Small Molecule Drugs, Biologics, Combination Therapies

    3) By Indication: Breast Cancer, Ovarian Cancer, Lung Cancer, Pancreas Cancer, Other Indications

    4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    5) By End-Users: Hospitals, Specialty Clinics, Other End-Users

    Subsegments:

    1) By Oral Oncogene Inhibitors: Small Molecule Inhibitors, Targeted Therapy Pills, Tyrosine Kinase Inhibitors (TKIs)

    2) By Injection Oncogene Inhibitors: Monoclonal Antibodies (mAbs), Peptide Receptor Radioligand Therapy (PRRT), Small Molecule Inhibitors (Injectable), Gene Therapy Injections

    What are the Emerging Market Trends Driving the Growth of the Oncogene Inhibitor  Industry?

    Key players in the oncogene inhibitor market are concentrating their efforts on creating new treatment strategies, including state-of-the-art functional genomic methods, to improve the accuracy and effectiveness of cancer therapies. Functional genomic methodologies are cutting-edge techniques that amalgamate diverse genomic, transcriptomic, and epigenomic data to comprehend gene functions and their part in illnesses such as cancer. For example, Delphia Therapeutics, a biotech firm based in the US, introduced an innovative method known as activation lethality in May 2024 to take advantage of cancer’s susceptibility to oncogene overexpression. Kevin Marks, Bill Sellers, and Mike Dillon, top oncology drug developers, have obtained $67 million in funding to push forward this approach. Activation lethality aims at the over-activation of oncogenes, genes whose mutation or overexpression stimulates cancer growth. Some cancer cells depend on this overexpression to live, and this technique kills these cells selectively by causing lethal stress through targeted intervention, while avoiding harm to healthy cells.

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/oncogene-inhibitor-global-market-report

    Which Regions Are Driving Growth in the Oncogene Inhibitor  Market?

    North America was the largest region in the oncogene inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncogene inhibitor  market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24635

    This Report Delivers Insight On:

    1. How big is the oncogene inhibitor  market, and how is it changing globally?

    2. Who are the major companies in the oncogene inhibitor  market, and how are they performing?

    3. What are the key opportunities and risks in the oncogene inhibitor  market right now?

    4. Which products or customer segments are growing the most in the oncogene inhibitor  market?

    5. What factors are helping or slowing down the growth of the oncogene inhibitor  market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Market Analysis on Gastrointestinal Cancer Industry – Insights for Corporate Strategy and R&D

    Market Analysis on Gastrointestinal Cancer Industry – Insights for Corporate Strategy and R&D

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Is the Forecast for the Gastrointestinal Cancer Market from 2024 to 2025?

    There has been a swift expansion in the market size of gastrointestinal cancer in the past few years. It is predicted to climb up from $24.09 billion in 2024 to $27.05 billion in 2025, progressing at a compound annual growth rate (CAGR) of 12.3%. The earlier growth phase can be linked to an increase in cases of gastrointestinal cancers, enhanced tobacco and alcohol usage, the rise in the elderly population, unhealthy eating habits, and progress in oncology diagnostic procedures and treatments.

    What Is the Projected Market Size of the Gastrointestinal Cancer Market?

    Achieving swift expansion in the coming years, the size of the gastrointestinal cancer market is projected to reach $42.45 billion by 2029, with a compound annual growth rate (CAGR) of 11.9%. The anticipated expansion during this forecast period is due in part to the growing preference for biomarker-driven therapies, an increase in consciousness regarding early screening, enhancements in healthcare infrastructure, government-driven programs for cancer support, and an amplified focus on minimally invasive techniques. The upcoming period will see a surge in trends like technological advancements related to diagnostic tools, innovative targeted therapies, breakthroughs in immunotherapy, the expanding use of artificial intelligence in treating cancer, along with continued research and development in the field of precision oncology.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24546&type=smp

    Who are the Major Competitors in the Gastrointestinal Cancer Market Outlook?

    Major companies operating in the gastrointestinal cancer market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Parexel International Corporation, Ipsen Biopharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Boehringer Ingelheim International GmbH, Zai Lab Limited, Taiho Pharmaceutical Co. Ltd.

    What Is Fueling Growth in the Gastrointestinal Cancer Market?

    The growing use of targeted therapies is set to stimulate the expansion of the market for gastrointestinal cancer. These specific treatments inhibit the growth of cancer cells by acting on particular molecular targets, thereby minimizing damage to healthy, normal cells. Targeted therapies are created to influence specific molecular pathways or genetic mutations responsible for a disease, particularly in cancer. Unlike conventional treatments like chemotherapy, which affect both healthy and diseased cells, targeted therapies concentrate on the unique features of a patient’s disease. These therapies for gastrointestinal (GI) cancer influence specific genes or proteins in charge of tumor growth, delivering accurate and efficient treatment. This leads to improved outcomes and fewer side effects compared to traditional chemotherapy. For example, in July 2023, as reported by the American Society of Gene & Cell Therapy (ASGCT), a professional membership organization based in the US, and Citeline, a US-based supplier of drugs and devices, there were 247 gene therapies in Phase II at the end of the first quarter (Q1) 2023. This number increased by 5% to 260 by the end of the second quarter (Q2). As such, the growing use of targeted therapies is fueling the expansion of the gastrointestinal cancer market.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=24546&type=smp

    Which Gastrointestinal Cancer Market Segments Are Growing the Fastest?

    The gastrointestinal cancer market covered in this report is segmented –

    1) By Cancer Type: Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer, Other Cancer Types

    2) By Diagnostics: Endoscopy, Biopsy, Molecular Diagnostics, Imaging, Other Diagnostics

    3) By Treatment: Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery, Other Treatments

    4) By End-User: Hospitals, Oncology Centers, Research Institutes, Diagnostic Laboratories, Other End-Users

    Subsegments:

    1) By Colorectal Cancer: Colon Cancer, Rectal Cancer, Recurrent Colorectal Cancer, Metastatic Colorectal Cancer

    2) By Stomach Cancer: Adenocarcinoma, Gastrointestinal Stromal Tumors (GIST), Lymphoma, Carcinoid Tumors

    3) By Esophageal Cancer: Adenocarcinoma, Squamous Cell Carcinoma, Small Cell Carcinoma, Other Rare Esophageal Tumors

    4) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Endocrine (Neuroendocrine) Pancreatic Tumors, Metastatic Pancreatic Cancer, Resectable Or Unresectable Tumors

    5) By Liver Cancer: Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma, Hepatoblastoma, Secondary (Metastatic) Liver Cancer

    6) By Other Cancer Types: Small Intestine Cancer, Anal Cancer, Gallbladder Cancer, Gastrointestinal Carcinoid Tumor

    Which Industry Trends Are Shaping the Future of the Gastrointestinal Cancer Market?

    Key players in the gastrointestinal cancer market are concentrating their efforts on the creation of innovative solutions, such as monoclonal antibody therapy, to enhance patient’s survival rates and lessen the negative impacts of treatment. This therapy involves the utilization of lab-made antibodies that can accurately identify and attach to cancer cells, aiding the immune system in its detection and eradication of these cells. To illustrate, Astellas Pharma Inc., a pharmaceutical firm based in Japan, rolled out VYLOY (zolbetuximab) in conjunction with fluoropyrimidine- and platinum-centric chemotherapy in September 2024, after getting the green light from the European Commission. This is the initial line of treatment for adults suffering from advanced, non-surgical locally-advanced or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma, in which tumors express claudin 18.2 (CLDN18.2). This nod from the European Commission makes VYLOY the only therapy available in the European Union that targets CLDN18.2, a biomarker found in roughly 38% of these patients. This stat is based on the encouraging results seen in the SPOTLIGHT and GLOW clinical trials.

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-cancer-global-market-report

    Which Countries Are Leading the Gastrointestinal Cancer Market?

    North America was the largest region in the gastrointestinal cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24546

    This Report Delivers Insight On:

    1. How big is the gastrointestinal cancer market, and how is it changing globally?

    2. Who are the major companies in the gastrointestinal cancer market, and how are they performing?

    3. What are the key opportunities and risks in the gastrointestinal cancer market right now?

    4. Which products or customer segments are growing the most in the gastrointestinal cancer market?

    5. What factors are helping or slowing down the growth of the gastrointestinal cancer market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model